# Sotera Health Co > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Sotera Health Co). ## Overview Sotera Health is a U.S.-based provider of sterilization, laboratory testing, and advisory services for healthcare and life-science supply chains. Its businesses include outsourced terminal sterilization and irradiation, microbiological and analytical testing, and cobalt-60 source supply and related services through Sterigenics, Nelson Labs, and Nordion. ## Products & services • Outsourced terminal sterilization and irradiation • Microbiological and analytical lab testing • Sterilization validation and advisory services • Cobalt-60 radiation sources and related services • Gamma irradiation system refurbishments and installation - **Sterilization Services** (55%) — Contract sterilization, irradiation, and validation services for medical, pharma, food, and industrial customers. - **Laboratory Testing and Advisory** (30%) — Microbiological, analytical chemistry, biocompatibility, toxicology, and regulatory advisory services. - **Cobalt-60 Products and Services** (15%) — Sale of Co-60 radiation sources plus installation, disposal, and related support services. - Outsourced terminal sterilization and irradiation - Microbiological and analytical lab testing - Sterilization validation and advisory services - Cobalt-60 radiation sources and related services - Gamma irradiation system refurbishments and installation ## Customers Customers are primarily medical device manufacturers, pharmaceutical companies, and other healthcare-related producers that need validated sterilization and testing to meet regulatory requirements. The company also serves food, agricultural, and advanced materials customers, while Nordion sells Co-60 to medical equipment makers and sterilization service providers. Relationships are typically recurring because customers embed these services into manufacturing and quality-control workflows. - **Medical device manufacturers** (primary) — Buy sterilization, validation, and lab testing to meet device safety and regulatory requirements. - **Pharmaceutical companies** (primary) — Buy microbiological testing, extractables/leachables, packaging validation, and sterilization support. - **Food and agricultural producers** (secondary) — Use irradiation services for product safety and shelf-life or contamination control. - **Advanced commercial materials customers** (secondary) — Use radiation processing for materials such as polymers, semiconductors, and gemstones. - **Medical equipment and sterilization service providers** (primary) — Buy Co-60 sources and related services for gamma irradiation and oncology applications. - Medical device makers needing validated sterilization and testing - Pharmaceutical companies requiring packaging and sterility assurance - Food and agricultural producers using irradiation services - Advanced materials customers using radiation processing - Medical equipment makers buying Co-60 sources ## Geography Sotera Health operates globally, with customers in more than 50 countries and 62 facilities worldwide. The United States is an important operating base, but the business also depends on international manufacturing sites, cross-border supply chains, and global regulatory regimes that affect sterilization and testing demand. - Customers in more than 50 countries - 62 facilities worldwide support sterilization and testing - U.S. is a major operating and regulatory center - International supply chains matter for customer manufacturing sites - Global operations create foreign-currency and compliance exposure ## Strategy The company is investing in capacity expansion, Co-60 development, and lab growth to support demand across its three businesses. It also seeks disciplined acquisitions and uses long-duration customer relationships and validation barriers to reinforce switching costs and recurring revenue. - **Capacity expansion** (medium-term) — More facility capacity supports customer demand and reduces bottlenecks in mission-critical services. - **Co-60 supply development** (medium-term) — Reliable isotope supply is central to Nordion's product and service offering. - **Lab growth** (medium-term) — Expanded testing capabilities support pharma and device customers and deepen recurring relationships. - **Disciplined M&A** (long-term) — Acquisitions can broaden capabilities and scale if integrated successfully. - Expand sterilization capacity at existing and new facilities - Develop and secure Co-60 supply for Nordion customers - Grow lab testing capacity for pharma and medical device work - Pursue disciplined acquisitions that fit the platform - Maintain customer validation and regulatory trust ## Risks The business is exposed to supply, regulatory, litigation, and operational risks because its services rely on hazardous materials and strict compliance standards. It also faces foreign exchange, leverage, and competitive risks, including substitution toward alternative sterilization technologies and customer insourcing of testing. - **EO and Co-60 supply disruption or price inflation** [high] — Sterilization and isotope supply are core inputs to the business and may be affected by geopolitics or sanctions. - **EO litigation and liability claims** [critical] — Past and future claims tied to EO emissions and facility operations can create settlement and legal expense. - **Regulatory compliance and approvals** [high] — Customers rely on the company to meet government and quality requirements, so failures can disrupt demand. - **Foreign currency exchange volatility** [medium] — The company serves customers across many countries and reports exposure to FX changes in results. - **Competition and substitution** [medium] — Customers may shift to X-ray sterilization, alternative suppliers, or in-house testing. - **Leverage and debt covenant constraints** [high] — Debt can limit flexibility and increase sensitivity to operating or legal shocks. - EO and Co-60 supply disruptions can constrain operations - Litigation from EO facilities can create large cash and legal costs - Regulatory changes can delay approvals or raise compliance costs - Foreign exchange moves affect international revenues and costs - Competition from X-ray and in-house labs can pressure demand ## Accounting Revenue recognition depends on whether services are satisfied at a point in time or over time, which affects quarterly timing across sterilization, testing, and product sales. Investors should also watch litigation provisions, asset retirement obligations, and derivative accounting, since hazardous-material facilities, debt hedges, and settlement estimates can materially affect reported earnings and balance-sheet values. - **Revenue recognition timing** — Service revenues and product revenues can move differently by period - **Litigation and contingency accruals** — Can materially affect operating expense and cash outflows - **Asset retirement obligations** — Affects long-lived asset and liability balances - **Interest rate derivatives** — Affects interest expense and other comprehensive income - **Goodwill and intangible impairment** — Could create non-cash charges - Point-in-time vs over-time revenue recognition affects timing - Service and product revenue mix can shift quarterly results - Litigation accruals and settlement estimates affect earnings - Asset retirement obligations reflect facility remediation costs - Interest-rate derivatives affect reported financing results --- *Last updated: 2026-04-29T04:59:35.982568+00:00*